EGFR + NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung ...
Renal & Urology News

Discordant Cystatin C vs Creatinine-Based eGFR Predicts Worse Kidney, CV Outcomes

Individual patients may have substantial differences in their eGFRcr and eGFRcys for estimating kidney function, which has prognostic implications.
EMBO Press

Closing the loop on EGFR therapy: decoding cetuximab response through circ-EGFR

Over the past decade, several tumor-based predictors of cetuximab efficacy have been identified, yet most function as ...
Healio

Race-neutral eGFR equation affects wait times, increasing transplants for Black patients

National implementation of a race-neutral eGFR equation contributed to more modifications and higher kidney transplantation rates for Black candidates, according to study data published in the Journal ...
HealthDay on MSN

ASN: Large Gap Between Creatinine-Based eGFR and Cystatin C-Based eGFR Tied to Worse Outcomes

In the outpatient setting, the presence of a cystatin C-based estimated glomerular filtration rate (eGFRcys) that is at least ...

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Detailed price information for Oric Pharmaceuticals Inc (ORIC-Q) from The Globe and Mail including charting and trades.